Abstract:ObjectiveThe purpose of this study was to find a new potent BRD4 inhibitor for the treatment of TNBC.MethodsHTRF based assay was applied to identify BRD4 inhibitors. Then, molecular docking was used to characterize the potential binding mechanism of the compound. After that, dialysis assay and ultracentrifuge assay were applied to test the reversible binding of 10-HCPT on BRD4(BD1) and BRD4(BD1), respectively. CESTA was used to test the binding of 10-HCPT to BRD4 in cellular level. Finally, CCK8 assay, flow cytometry, western blotting and xenograft model bearing MDA-MB-231 cells were utilized to test the activity and mechanism of 10-HCPT on MDA-MB-231 cells in vitro and in vivo.Results10-HCPT was identified to be a strong inhibitor of BRD4 with IC50 = 928.1 nM against the BRD4(BD1) recombinant and IC50 = 865.8 nM versus the BRD4(BD2) recombinant, adopting a drug repositioning approach. Moreover, we found that 10-HCPT can inhibit BRD4 reversibly with the aid of dilution assay and dialysis experiments. At the cellular level, 10-HCPT binds to BRD4 and inhibits the growth of MDA-MB-231, a triple-negative breast cancer (TNBC) cell line that is partly dependent on the level of BRD4. Meanwhile, 10-HCPT can induce apoptosis as well as the decreasing amount of C-MYC, a substrate of BRD4, Ki-67, BCL-XL, and BCl-2, as well as induce the cleavage of caspase 3. In vivo xenograft model bearing MDA-MB-231 cells indicated that 10-HCPT can strongly inhibit MDA-MB-231 proliferation in BRD4 partially dependent behavior with minimal toxicity.ConclusionBRD4 may be a new potential target for 10-HCPT and provide new insight into the future 10-HCPT-based TNBC therapies.

Discovery of Novel Dual-Target Inhibitor of Bromodomain-Containing Protein 4/Casein Kinase 2 Inducing Apoptosis and Autophagy-Associated Cell Death for Triple-Negative Breast Cancer Therapy

Discovery of Dual CDK6/BRD4 Inhibitor Inducing Apoptosis and Increasing the Sensitivity of Ferroptosis in Triple-Negative Breast Cancer.

Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer.

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer

Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors

Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.

Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives As Bromodomain-Containing Protein 4/histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells.

An optimized BRD4 inhibitor effectively eliminates NF-κB-driven triple-negative breast cancer cells

Design, Synthesis and Biological Evaluation of Novel 6-Phenyl-1,3a,4,10b-tetrahydro-2h-benzo[c]thiazolo[4,5-e]azepin-2-one Derivatives As Potential BRD4 Inhibitors.

Design, Synthesis and Anti-Ovarian Cancer Activities of Thieno[2,3-D] Pyrimidine Based Chimeric BRD4 Inhibitor/nitric Oxide-Donator

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy

Rational Design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol Derivatives As Novel Bromodomain-Containing Protein 4 Inhibitors.

Identification of (S)-10-Hydroxycamptothecin as a potent BRD4 inhibitor for treating triple-negative breast cancer

Discovery of First-in-Class Dual PARP and EZH<sub>2</sub> Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA

Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both In Vitro and In Vivo

Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA